Compare Southwest Airlines Co (LUV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Neurocrine Biosciences Inc — how do they compare? Southwest Airlines Co trades at $41.41 (market cap $20.23B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LUV | NBIX | |
|---|---|---|
Market Cap | $20.23B | $14.60B |
Volume | 14,560,422 | 1,075,694 |
Sector | Industrials | Health |
52-Week High | $54.80 | $185.50 |
52-Week Low | $29.67 | $123.10 |
Typical Hold Time | 65 Days | 23 Days |
Enterprise Value | $23.33B | $14.61B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $28.06B in 2025 to projected $30.1B in 2026, though net margins remain thin at 2.78%. Recent earnings show volatility with a Q2 2026 beat but Q1 2026 miss, while analyst consensus leans slightly bullish with a $49.61 price target representing 19% upside potential.
LUV presents a transformation story with new revenue initiatives driving growth, but faces headwinds from high fuel costs and competitive pressures. The stock offers value with reasonable P/E of 26.08 and P/S of 0.73, though investors should monitor execution of commercial initiatives and fuel cost management. Near-term catalyst includes Q3 2026 earnings release on October 21, 2026.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
